Skip to main content
. Author manuscript; available in PMC: 2023 Dec 15.
Published in final edited form as: Eur J Med Chem. 2022 Oct 5;244:114807. doi: 10.1016/j.ejmech.2022.114807

Table 6.

Inhibitory potencies against HDAC1, HDAC2, HDAC3, HDAC4, HDAC6 and HDAC8. Highlighted in red are the most selective inhibitors.

Compound IC50 (nM)
HDAC1 HDAC2 HDAC3 HDAC4 HDAC6 HDAC8
65 120 ± 20 3200 ± 300 230 ± 20 2600 ± 200 100 ± 10 11 ± 2
61 56 ± 3 580 ± 20 210 ± 10 430 ± 30 82 ± 7 5.3 ± 1.6
85 120 ± 10 2400 ± 100 59 ± 1 1700 ± 200 35 ± 4 10 ± 1
69 61 ± 4 1800 ± 100 72 ± 2 1100 ± 100 38 ± 3 4.1 ± 0.6
55 100 ± 10 1400 ± 100 180 ± 10 1600 ± 200 440 ± 20 51 ± 5
86 110 ± 10 3600 ± 300 99 ± 9 2300 ± 300 210 ± 20 30 ± 3
64 160 ± 10 4900 ± 200 270 ± 20 2700 ± 300 260 ± 50 52 ± 7
83 4100 ± 100 2500 ± 400 120 ± 10 1900 ± 400 100 ± 10 8.9 ± 0.7
58 180 ± 10 4800 ± 300 620 ± 50 2500 ± 300 350 ± 20 21 ± 3
84 97 ± 2 360 ± 40 100 ± 10 2500 ± 100 37 ± 10 13 ± 1
SAHA 33 ± 1 96 ± 10 20 ± 1 12000 ± 800 33 ± 3 540 ± 10

Potencies were determined using a chemiluminescent HDAC activity assay, with the mean and standard error of at least three independent trials shown (Supporting Information, Figs. S22–S27, Table S2–S7). The IC50 values for SAHA were previously reported using the same assay [38].